Drug Profile


Alternative Names: CGP 28238; CGS 28238; SH 459; ZK 38997

Latest Information Update: 03 Sep 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Imperial Innovations
  • Class Antirheumatics; Indans; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Preterm labour; Rheumatic disorders

Most Recent Events

  • 19 Oct 1999 Preclinical development for Preterm labour in United Kingdom (Unknown route)
  • 15 Sep 1997 Investigation in Rheumatic disorders (PO)
  • 12 Sep 1997 A study in patients with osteoarthritis has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top